DuPont Applied BioSciences has turned to MBI International to join the DuPont team in evaluating the commercial viability of an important bio-based product line. MBI International is a leader in bridging the gap between research and commercialization through collaborative de-risking of bio-based technologies. MBI’s unique “Collaborative De-Risking” process systematically addresses technological uncertainties, which impede new technologies from getting to market.
LANSING, Mich. (Business Wire EON) December 2, 2008 -- "We are very excited that DuPont Applied BioSciences has chosen MBI as a partner to help de-risk this important new product line," stated Dr. Bobby Bringi, recently appointed President of MBI International. "We had the opportunity to work with DuPont Applied BioSciences on an initial phase of this project, and are proud that they have chosen to extend this partnership with MBI."
MBI International fits a unique niche in the marketplace. Virtually all bio-based technology developments that come from the lab need to go through a process development and scale-up stage to determine commercial viability. Once the uncertainties or risks associated with early technological developments are mitigated via de-risking, a company like DuPont Applied BioSciences is better positioned to make product-related investments.
MBI has built a multi-disciplinary team of scientists and engineers, as well as the required pilot-plant facilities, to work collaboratively with industry partners to help address the risks associated with bringing bio-based technologies to market. MBI also provides connectivity with both Michigan State University and the greater university research community to help solve complex problems.
"DuPont Applied BioSciences is pleased to continue our collaboration with MBI on this important new product line,
Copyright©2008 Vocus, Inc.
All rights reserved